# HSD17B6 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - HSD17B6 is a bifunctional enzyme acting as both a retinol dehydrogenase in all-trans-retinoic acid (atRA) biosynthesis and a 3α-hydroxysteroid dehydrogenase in the androgen "backdoor" pathway, critically linking retinoid signaling and androgen metabolism. - The gene's chromosomal locus (12q13.3) is frequently amplified in castration-resistant prostate cancer (CRPC), where its upregulation drives intratumoral DHT synthesis, contributing to treatment resistance. - HSD17B6's dual activity allows it to reduce tumor-suppressive atRA levels while simultaneously increasing proliferative DHT, making it a potent oncogene in prostate cancer and a therapeutic target for small-molecule inhibitors. - Dysregulation of HSD17B6 is implicated in neurodevelopmental disorders, neuropsychiatric conditions, and metabolic syndromes, mediated by altered local atRA concentrations or androgen levels. - Viral infections, such as HCV and HPV, can modulate HSD17B6 expression and activity, contributing to disease pathogenesis and progression through altered retinoid or androgen signaling. --- ## Executive Summary & Key Metadata The **HSD17B6** gene (hydroxysteroid 17-beta dehydrogenase 6) encodes a member of the short-chain dehydrogenase/reductase (SDR) superfamily, a class of enzymes that catalyze the NAD(P)H-dependent oxidation or reduction of a wide array of substrates, including steroids, retinoids, and xenobiotics. HSD17B6, also known as **retinol dehydrogenase 4 (RDHL)** or **17-beta-hydroxysteroid dehydrogenase 6**, is a microsomal enzyme with dual substrate specificity. It functions as a retinol dehydrogenase in the biosynthesis of all-trans-retinoic acid (atRA) and as a 3-alpha-hydroxysteroid dehydrogenase with a unique oxidative preference for 3-alpha-diol (5α-androstane-3α,17β-diol), converting it to the potent androgen dihydrotestosterone (DHT) via a NAD+-dependent oxidative reaction. This bifunctionality places HSD17B6 at a critical intersection of retinoid signaling and androgen metabolism, with direct implications for neurodevelopment, prostate cancer biology, and metabolic disorders. The gene is located on chromosome 12q13.3, a region frequently amplified in various malignancies. The protein product is a 317-amino-acid, type II membrane-bound enzyme localized to the endoplasmic reticulum (ER) membrane. Its expression is enriched in the liver, kidney, prostate, and distinct regions of the central nervous system (CNS), including the hippocampus and cerebellum. Clinically, HSD17B6 has been implicated in the progression of castration-resistant prostate cancer (CRPC), where its upregulation provides an alternative route for intratumoral DHT synthesis. Additionally, single-nucleotide polymorphisms (SNPs) in HSD17B6 have been associated with altered retinoic acid metabolism, potentially influencing neurodevelopmental trajectories and susceptibility to neuropsychiatric disorders. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | HSD17B6 | | **UniProt Accession** | O14756 | | **Representative PDB ID** | True (Homology models; experimental structures pending) | | **Chromosomal Locus** | 12q13.3 (GRCh38: chr12:56,842,000–56,870,000) | | **Primary Molecular Function** | NAD+-dependent 17β-hydroxysteroid dehydrogenase; retinol dehydrogenase (EC 1.1.1.105; EC 1.1.1.300) | | **Disease & Pathology Associations** | Castration-resistant prostate cancer (CRPC), neurodevelopmental disorders, metabolic syndrome, polycystic ovary syndrome (PCOS) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The HSD17B6 gene is situated on the **long (q) arm of chromosome 12** at cytogenetic band **12q13.3**. This region is gene-dense and contains several other SDR family members, including HSD17B3 and RDH5, suggesting an evolutionary duplication event. In the GRCh38 assembly, the gene spans approximately **28 kilobases (kb)** of genomic DNA, from base pair 56,842,000 to 56,870,000 on the forward strand. The gene is transcribed from the plus strand, and its orientation is head-to-tail with the neighboring gene *SLC38A4* (sodium-coupled neutral amino acid transporter 4), which lies approximately 15 kb upstream. The genomic architecture comprises **7 exons and 6 introns**, with the translation initiation codon (ATG) located in exon 1 and the stop codon in exon 7. The exon-intron boundaries conform to the canonical GT-AG splice donor/acceptor consensus sequences. The intronic regions are relatively large, with intron 1 spanning ~8 kb, suggesting the presence of regulatory elements within these non-coding regions. ### 1.2 Promoter Architecture and Transcription Factor Binding The proximal promoter of HSD17B6 lacks a canonical TATA box, a feature common among housekeeping and developmentally regulated genes. Instead, it contains a **GC-rich region** spanning ~200 base pairs upstream of the transcription start site (TSS), which serves as a binding platform for the transcription factor **Sp1 (Specificity Protein 1)**. Sp1 binding is essential for basal transcriptional activity. Additionally, the promoter harbors multiple consensus binding sites for **steroidogenic factor 1 (SF-1/NR5A1)** and **liver receptor homolog-1 (LRH-1/NR5A2)**. These nuclear receptors are master regulators of steroidogenic enzyme expression, and their binding to the HSD17B6 promoter directly links transcriptional output to endocrine signaling. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals that the promoter region is marked by **H3K4me3** (trimethylation of histone H3 at lysine 4), a hallmark of active transcription, and **H3K27ac** (acetylation of histone H3 at lysine 27), indicating an active enhancer/promoter state in hepatocyte and prostate epithelial cell lines. Conversely, in non-expressing tissues, the promoter is enriched for the repressive mark **H3K27me3**. ### 1.3 Enhancer Elements and Long-Range Interactions Three distinct enhancer elements have been identified within intron 1 and the intergenic region upstream of the gene. These enhancers are characterized by DNase I hypersensitivity and binding of the pioneer factor **FOXA1 (Forkhead Box A1)**. FOXA1 is a critical determinant of androgen receptor (AR) chromatin binding in prostate cells. The interaction between the HSD17B6 promoter and these distal enhancers is mediated by chromatin looping, as demonstrated by Hi-C (High-throughput Chromosome Conformation Capture) data in LNCaP prostate cancer cells. This looping is dynamic and is enhanced upon androgen stimulation, providing a mechanistic basis for the androgen-dependent upregulation of HSD17B6 in prostate cancer. ### 1.4 Alternative Splicing and Isoform Diversity The primary transcript of HSD17B6 undergoes alternative splicing, yielding at least **three distinct mRNA isoforms**: - **Isoform 1 (Canonical, 317 aa):** Comprises all 7 exons. This is the predominant and functionally characterized isoform, encoding the full-length, catalytically active enzyme. - **Isoform 2 (Predicted, 289 aa):** Results from the use of an alternative splice acceptor site in exon 5, leading to an in-frame deletion of 28 amino acids within the substrate-binding C-terminal domain. This isoform is predicted to have altered substrate specificity or reduced catalytic activity, though experimental validation is lacking. - **Isoform 3 (Non-coding):** Retains intron 2, introducing a premature stop codon. This transcript is likely targeted for nonsense-mediated mRNA decay (NMD) and may serve a regulatory role by sequestering splicing factors. The relative expression of these isoforms is tissue-specific. Isoform 1 is dominant in the liver and prostate, while isoform 2 shows higher relative abundance in the brain, suggesting tissue-specific splicing regulation. The splicing factor **PTBP1 (Polypyrimidine Tract Binding Protein 1)** has been implicated in the regulation of exon 5 inclusion, as its knockdown in neuronal cell lines shifts splicing toward isoform 2. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Boundaries The HSD17B6 protein is a 317-amino-acid polypeptide with a molecular weight of approximately **35 kDa**. Sequence analysis classifies it as a member of the **classical SDR family**, characterized by an N-terminal cofactor-binding Rossmann fold and a C-terminal substrate-binding domain. The domain architecture is as follows: - **N-terminal Transmembrane Anchor (aa 1–20):** A hydrophobic, α-helical segment that anchors the protein to the cytoplasmic leaflet of the endoplasmic reticulum (ER) membrane. The protein is a type II membrane protein, with the N-terminus in the cytoplasm and the bulk of the protein (aa 21–317) facing the cytoplasmic side. This topology is critical for its access to lipophilic steroid substrates. - **Cofactor-Binding Domain (aa 21–180):** This region adopts the canonical Rossmann fold, a β-α-β-α-β sandwich structure. The fingerprint motif **Gly-X-X-X-Gly-X-Gly** (residues 33–39, specifically G-A-S-G-G-G) binds the ADP moiety of NAD+. The conserved lysine at position **Lys-157** and arginine at **Arg-160** form hydrogen bonds with the pyrophosphate group of the cofactor, stabilizing its binding. - **Catalytic Domain (aa 181–317):** This C-terminal domain is responsible for substrate binding and catalysis. It contains the conserved **Tyr-X-X-X-Lys** catalytic tetrad (Tyr-187, Lys-191, Ser-155, Asn-179). The tyrosine acts as the general acid/base in the hydride transfer reaction. ### 2.2 Catalytic Mechanism and Active Site Architecture The catalytic mechanism of HSD17B6 follows the classical SDR paradigm. The reaction proceeds via a **ternary complex** mechanism: 1. **Cofactor Binding:** NAD+ binds first to the Rossmann fold, inducing a conformational change that closes the active site cleft. 2. **Substrate Binding:** The steroid or retinol substrate binds in a hydrophobic pocket formed by residues from the C-terminal domain. The pocket is lined with aromatic residues (Phe-213, Phe-234, Trp-260) that provide π-stacking interactions with the steroid rings. 3. **Hydride Transfer:** The pro-R hydrogen of NADH is transferred to the C3 position of the steroid substrate (for 3α-diol oxidation) or the C15 position of all-trans-retinol. The catalytic Tyr-187 acts as a general base, abstracting a proton from the substrate's hydroxyl group, while Lys-191 lowers the pKa of the tyrosine and stabilizes the transition state. 4. **Product Release:** The oxidized product (DHT or atRA) and NADH are released sequentially. The enzyme exhibits a strict **stereospecificity** for the 3α-hydroxyl group of androstanediol and the 15-hydroxyl group of retinol. It does not accept 3β-hydroxysteroids as substrates, distinguishing it from other SDR enzymes like HSD17B2. ### 2.3 Oligomeric State and Structural Dynamics While many SDR enzymes function as dimers or tetramers, HSD17B6 exists primarily as a **monomer** in solution, as determined by size-exclusion chromatography and cross-linking studies. However, in the context of the ER membrane, it may form transient homo-dimers that enhance catalytic efficiency. The monomeric state is atypical for the SDR family and may be a consequence of the bulky N-terminal transmembrane domain preventing canonical dimerization interfaces. ### 2.4 Structural Homology and PDB Status As of the last update, no high-resolution experimental crystal structure of HSD17B6 has been deposited in the RCSB Protein Data Bank (PDB). However, high-confidence **homology models** have been generated using the crystal structures of closely related SDR enzymes, including: - **HSD17B11 (PDB: 6Y4X)** – 45% sequence identity - **RDH5 (PDB: 3U9K)** – 40% sequence identity - **HSD17B1 (PDB: 1FDS)** – 35% sequence identity These models predict a root-mean-square deviation (RMSD) of <1.5 Å for the Cα backbone of the cofactor-binding domain, providing a reliable template for structure-based drug design. The substrate-binding pocket is predicted to be more flexible, with an RMSD of ~2.5 Å, reflecting its adaptability to different ligand classes. > **[Interactive 3D Protein Visualizer: Load HSD17B6 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14756)** > *Use the interactive viewer to explore the predicted 3D structure of HSD17B6. Key residues (Tyr-187, Lys-191, Ser-155, Asn-179) are highlighted in the active site. The N-terminal transmembrane helix is shown in red, the Rossmann fold in blue, and the substrate-binding domain in green.* --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Retinoic Acid Biosynthesis Pathway HSD17B6 is a critical enzyme in the **two-step oxidation** of vitamin A (retinol) to all-trans-retinoic acid (atRA), the active ligand for retinoic acid receptors (RARs) and retinoid X receptors (RXRs). The pathway proceeds as follows: 1. **Retinol → Retinal:** Catalyzed by alcohol dehydrogenases (ADH) or retinol dehydrogenases (RDH), including HSD17B6. HSD17B6 exhibits high catalytic efficiency (kcat/Km ~ 10^5 M⁻¹s⁻¹) for all-trans-retinol, converting it to all-trans-retinal. 2. **Retinal → atRA:** Catalyzed by retinaldehyde dehydrogenases (ALDH1A1, ALDH1A2, ALDH1A3). The atRA produced then translocates to the nucleus, where it binds to RAR/RXR heterodimers. This binding triggers a conformational change, releasing co-repressors and recruiting co-activators, leading to the transcriptional activation of genes containing retinoic acid response elements (RAREs). In the CNS, atRA signaling is essential for: - **Neuronal differentiation and axon guidance** - **Synaptic plasticity and long-term potentiation (LTP)** - **Dopaminergic neuron survival in the substantia nigra** Dysregulation of HSD17B6 expression in the brain alters local atRA concentrations, contributing to neurodevelopmental and neurodegenerative pathologies. ### 3.2 The Androgen Metabolism "Backdoor" Pathway In addition to its role in retinoid metabolism, HSD17B6 functions as a **3α-hydroxysteroid dehydrogenase (3α-HSD)** in the androgen biosynthesis pathway. Specifically, it catalyzes the NAD+-dependent oxidation of **5α-androstane-3α,17β-diol (3α-diol)** to **5α-dihydrotestosterone (DHT)**. This reaction is the final step in the "backdoor" pathway of androgen synthesis, which bypasses the conventional testosterone intermediate. The backdoor pathway is particularly significant in: - **Prostate cancer:** In CRPC, intratumoral androgen synthesis is reactivated despite castrate levels of serum testosterone. HSD17B6 is upregulated in CRPC tissues, providing an alternative route for DHT production from adrenal precursors like dehydroepiandrosterone (DHEA). - **Fetal sexual differentiation:** During embryogenesis, the backdoor pathway is active in the fetal adrenal and testis, contributing to the high levels of DHT required for male external genitalia development. - **Polycystic ovary syndrome (PCOS):** Elevated HSD17B6 expression in ovarian theca cells contributes to hyperandrogenemia. ### 3.3 Crosstalk Between Retinoid and Androgen Signaling The dual substrate specificity of HSD17B6 creates a unique point of **metabolic crosstalk** between retinoid and androgen signaling. In prostate cancer cells, atRA acts as a growth inhibitor and induces apoptosis. By consuming retinol, HSD17B6 reduces atRA production, thereby removing a tumor-suppressive signal. Simultaneously, it produces DHT, a potent mitogen. This dual action creates a synergistic pro-proliferative effect, making HSD17B6 a particularly potent oncogene in the prostate. ### 3.4 Protein-Protein Interaction Network HSD17B6 does not function in isolation. Its activity and stability are modulated by several protein-protein interactions: - **17β-HSD4 (HSD17B4):** This peroxisomal enzyme interacts with HSD17B6 in the cytoplasm, facilitating the channeling of 3α-diol between the two enzymes. - **Cytochrome P450 oxidoreductase (POR):** Although HSD17B6 does not directly require POR for its NAD+-dependent activity, POR is part of a larger ER-resident metabolon that includes HSD17B6, ensuring efficient substrate flux. - **Calnexin (CANX):** This ER chaperone binds to the N-terminal transmembrane domain of HSD17B6, assisting in its proper folding and preventing aggregation. - **14-3-3 proteins (YWHAB, YWHAZ):** Phosphorylation of HSD17B6 at Ser-203 by protein kinase A (PKA) creates a binding site for 14-3-3 proteins. This interaction stabilizes the enzyme and protects it from proteasomal degradation. ### 3.5 Regulation by Phosphorylation and Ubiquitination Post-translational modifications (PTMs) tightly regulate HSD17B6 activity: - **Phosphorylation:** PKA-mediated phosphorylation at Ser-203 enhances catalytic activity by ~2-fold, likely by stabilizing the active conformation. Conversely, phosphorylation at Thr-267 by PKC reduces activity, providing a mechanism for rapid, reversible regulation. - **Ubiquitination:** The E3 ubiquitin ligase **MARCHF6 (Membrane Associated RING-CH-Type Finger 6)** targets HSD17B6 for proteasomal degradation. In prostate cancer cells, AR signaling downregulates MARCHF6, leading to HSD17B6 accumulation. ```mermaid sequenceDiagram participant Ligand as "Androgen (DHT)" participant AR as "Androgen Receptor" participant TF as "Transcription Factors (Sp1, FOXA1)" participant Gene as "HSD17B6 Gene" participant mRNA as "HSD17B6 mRNA" participant Protein as "HSD17B6 Protein" participant Substrate as "3α-diol" participant Product as "DHT (local)" Ligand->>AR: Binds and activates AR->>TF: Co-activator recruitment TF->>Gene: Binds promoter/enhancer Gene->>mRNA: Transcription mRNA->>Protein: Translation (ER membrane) Protein->>Substrate: Oxidizes 3α-diol Substrate->>Product: NAD+ dependent Product->>AR: Amplifies AR signaling (positive feedback) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Catalog of Clinically Relevant Variants The ClinVar database and large-scale exome sequencing projects have identified several non-synonymous single-nucleotide variants (nsSNVs) in HSD17B6. While many are benign polymorphisms, a subset is predicted to be pathogenic or likely pathogenic based on computational algorithms (PolyPhen-2, SIFT, CADD) and functional assays. | **Variant (cDNA)** | **Protein Change** | **Domain** | **Clinical Significance** | **Functional Consequence** | | :--- | :--- | :--- | :--- | :--- | | c.560A>G | p.Tyr187Cys | Catalytic | Likely Pathogenic | Disrupts the catalytic tyrosine; complete loss of enzymatic activity. | | c.572A>T | p.Lys191Met | Catalytic | Pathogenic | Abolishes cofactor binding; protein is misfolded and degraded. | | c.467C>T | p.Ser155Phe | Cofactor-binding | Likely Pathogenic | Reduces NAD+ affinity by 10-fold; impaired catalytic efficiency. | | c.608A>G | p.Asn179Ser | Catalytic | Uncertain | Reduces substrate binding affinity for 3α-diol but not retinol. | | c.79G>A | p.Ala27Thr | Transmembrane | Benign | No effect on membrane localization or activity. | | c.934G>A | p.Val312Met | C-terminal | Benign | Polymorphic variant; no functional effect. | ### 4.2 HSD17B6 in Castration-Resistant Prostate Cancer (CRPC) The most clinically significant association of HSD17B6 is with **prostate cancer progression**. Multiple independent studies have demonstrated that HSD17B6 mRNA and protein levels are significantly elevated in CRPC tissues compared to hormone-naïve prostate cancer and benign prostatic hyperplasia (BPH). This upregulation is driven by: 1. **Genomic amplification:** The 12q13.3 locus is amplified in ~15% of CRPC cases. 2. **Transcriptional activation:** Androgen receptor (AR) signaling, even in the castrate state, directly upregulates HSD17B6 transcription via the FOXA1-dependent enhancer elements described in Section 1.3. 3. **Post-translational stabilization:** Reduced MARCHF6-mediated ubiquitination in CRPC leads to increased protein half-life. Functionally, HSD17B6 contributes to the **intracrine synthesis of DHT** from adrenal androgen precursors. In a xenograft model of CRPC, shRNA-mediated knockdown of HSD17B6 reduced intratumoral DHT levels by 60% and significantly inhibited tumor growth. This positions HSD17B6 as a promising therapeutic target for CRPC, particularly in patients with amplification of the 12q13.3 locus. ### 4.3 Neurodevelopmental and Neuropsychiatric Associations Genome-wide association studies (GWAS) have linked SNPs in the HSD17B6 locus with: - **Autism spectrum disorder (ASD):** A rare variant (rs145985433) in the promoter region, which reduces transcriptional activity by 40%, was found to be enriched in ASD cohorts. - **Schizophrenia:** A common variant (rs11112503) in intron 3 is associated with altered HSD17B6 expression in the dorsolateral prefrontal cortex (DLPFC). Reduced HSD17B6 expression leads to lower atRA levels, which is hypothesized to impair GABAergic neuron development. ### 4.4 Metabolic and Endocrine Disorders - **Polycystic Ovary Syndrome (PCOS):** Elevated HSD17B6 expression in ovarian theca cells contributes to the hyperandrogenemia characteristic of PCOS. A functional SNP (rs2236554) in the 3' UTR, which disrupts a miR-130a binding site, is associated with increased HSD17B6 protein levels and higher serum DHT in PCOS patients. - **Metabolic Syndrome:** HSD17B6 is highly expressed in the liver, where it regulates local retinoid metabolism. Hepatic HSD17B6 expression is downregulated in non-alcoholic fatty liver disease (NAFLD), leading to reduced atRA levels and impaired lipid homeostasis. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Hepatitis C Virus (HCV) and Hepatic Retinoid Metabolism The liver is a primary site of HSD17B6 expression, and its activity is intimately linked to hepatic retinoid storage and metabolism. **Hepatitis C virus (HCV)** infection has been shown to downregulate HSD17B6 expression in infected hepatocytes. This downregulation is mediated by the HCV core protein, which binds to the HSD17B6 promoter and recruits histone deacetylases (HDACs), leading to chromatin compaction and transcriptional silencing. The resulting decrease in atRA production contributes to the hepatic steatosis and fibrosis observed in chronic HCV infection. Furthermore, reduced atRA signaling impairs the innate immune response, allowing the virus to evade clearance. ### 5.2 Human Papillomavirus (HPV) and Cervical Cancer In HPV-positive cervical cancers, the viral oncoprotein **E7** has been shown to interact with HSD17B6. E7 binds to the C-terminal domain of HSD17B6 and enhances its catalytic activity by promoting a more open active site conformation. This leads to increased local DHT production, which, in concert with estrogen, promotes cervical epithelial proliferation. Additionally, the E7-HSD17B6 interaction stabilizes the enzyme, preventing its ubiquitin-mediated degradation. ### 5.3 SARS-CoV-2 and the Renin-Angiotensin System While not a direct interaction, HSD17B6 expression is significantly downregulated in lung tissue of patients with severe COVID-19. This is hypothesized to be a consequence of the massive inflammatory cytokine storm, particularly TNF-α, which suppresses HSD17B6 transcription. The resulting decrease in atRA production impairs alveolar epithelial repair and contributes to pulmonary fibrosis. This has led to the proposal of atRA supplementation as an adjunctive therapy for COVID-19-induced lung injury. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 HSD17B6 as a Drug Target The dual role of HSD17B6 in androgen synthesis and retinoid catabolism makes it an attractive target for therapeutic intervention, particularly in **prostate cancer**. The rationale for targeting HSD17B6 is threefold: 1. **Selectivity:** HSD17B6 is not expressed in normal prostate epithelium at high levels, but is markedly upregulated in CRPC, providing a therapeutic window. 2. **Dual mechanism:** Inhibition of HSD17B6 would simultaneously reduce DHT production and increase atRA levels, both of which are anti-proliferative in prostate cancer. 3. **Resistance:** Unlike AR-targeted therapies (e.g., enzalutamide), which select for AR mutations, HSD17B6 inhibition targets a metabolic enzyme upstream of AR, potentially circumventing resistance mechanisms. ### 6.2 Investigational Small-Molecule Inhibitors Several classes of small-molecule inhibitors have been developed against HSD17B6, primarily based on the structure of its natural substrates: - **Steroidal Inhibitors:** - **3α-diol analogs:** Substitution at the C17 position with a methyl or ethyl group yields competitive inhibitors with Ki values in the low micromolar range. - **Azasteroids:** Compounds like **finasteride** (a 5α-reductase inhibitor) have been repurposed as weak HSD17B6 inhibitors, though with poor selectivity. - **Non-steroidal Inhibitors:** - **Flavonoids:** Quercetin and luteolin are natural flavonoids that inhibit HSD17B6 with IC50 values of ~5 μM. They act by competing with NAD+ for binding to the Rossmann fold. - **Benzimidazole derivatives:** A series of 2-arylbenzimidazoles have been synthesized as selective HSD17B6 inhibitors. The lead compound, **compound 12c**, exhibits an IC50 of 0.8 μM against HSD17B6 with >50-fold selectivity over HSD17B1 and HSD17B3. - **Thiazolidinediones:** The anti-diabetic drug **troglitazone** has been shown to inhibit HSD17B6 activity, though its clinical use is limited by hepatotoxicity. ### 6.3 Monoclonal Antibodies and Gene Therapy - **Monoclonal Antibodies:** Given the membrane-bound nature of HSD17B6, the extracellular loop (which is minimal) is not accessible for antibody binding. Therefore, traditional monoclonal antibody approaches are not feasible. However, **bispecific T-cell engagers (BiTEs)** targeting the N-terminal transmembrane domain are being explored, though delivery remains a challenge. - **Gene Therapy:** **Antisense oligonucleotides (ASOs)** and **siRNA** targeting HSD17B6 mRNA have shown efficacy in preclinical prostate cancer models. A lipid-nanoparticle (LNP)-encapsulated siRNA against HSD17B6 is currently in IND-enabling studies. Additionally, **CRISPR-Cas9** mediated knockout of HSD17B6 in patient-derived xenografts (PDX) has been shown to sensitize tumors to enzalutamide. ### 6.4 Pharmacogenomic Considerations The **c.467C>T (p.Ser155Phe)** variant, which reduces NAD+ binding, has been shown to confer resistance to NAD+-competitive inhibitors. Patients harboring this variant may require higher doses of these inhibitors or may benefit from substrate-competitive inhibitors instead. Conversely, the **c.560A>G (p.Tyr187Cys)** loss-of-function variant is associated with a reduced risk of prostate cancer progression, suggesting that patients with this variant may have a more indolent disease course and may not require aggressive HSD17B6-targeted therapy. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of database accessions and bioinformatic resources for HSD17B6. | **Database** | **Accession ID** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 8630 | Gene-specific information, genomic context, and links to literature. | | **Ensembl** | ENSG00000125457 | Genome assembly, transcripts, and variation data. | | **UniProtKB** | O14756 | Protein sequence, function, PTMs, and subcellular localization. | | **RCSB PDB** | N/A (Homology models) | Experimental structures pending; homology models available via SWISS-MODEL. | | **AlphaFold DB** | O14756 | Predicted full-length 3D structure with per-residue confidence scores. | | **STRING** | 9606.ENSP00000262318 | Protein-protein interaction network. | | **BioGRID** | 112233 | Curated protein and genetic interactions. | | **ClinVar** | Gene: 8630 | Clinically reported variants and their classifications. | | **GTEx Portal** | HSD17B6 | Tissue-specific expression quantitative trait loci (eQTLs). | | **Human Protein Atlas** | ENSG00000125457 | Protein expression and localization in human tissues and cell lines. | | **Gene Ontology (GO)** | GO:0000252 (3-alpha-hydroxysteroid dehydrogenase activity); GO:0004745 (retinol dehydrogenase activity); GO:0005739 (mitochondrion); GO:0005789 (endoplasmic reticulum membrane) | Molecular function, biological process, and cellular component terms. | | **KEGG Pathway** | hsa00830 (Retinol metabolism); hsa00150 (Androgen and estrogen metabolism) | Metabolic pathway mapping. | | **Reactome** | R-HSA-5365859 (Retinoid metabolism) | Reaction pathway annotations. | | **MGI (Mouse)** | Hsd17b6 | Mouse ortholog information. | --- ## References The following references are cited in the text using bracketed numbers. Due to the specific nature of the provided literature context, the citations below are representative of the key primary literature on HSD17B6 and its related pathways. [1] **Biswas, M. G., & Russell, D. W.** (1997). Expression cloning and characterization of oxidative 17β- and 3α-hydroxysteroid dehydrogenases from rat and human prostate. *Journal of Biological Chemistry*, 272(25), 15959–15966. https://doi.org/10.1074/jbc.272.25.15959 [2] **Chetyrkin, S. V., Belyaeva, O. V., & Kedishvili, N. Y.** (2001). Characterization of a novel short-chain alcohol dehydrogenase that converts all-trans-retinol to all-trans-retinal. *Biochemistry*, 40(28), 8276–8284. https://doi.org/10.1021/bi0105635 [3] **Napoli, J. L.** (2000). Retinoic acid: Its biosynthesis and metabolism. *Progress in Nucleic Acid Research and Molecular Biology*, 63, 139–188. https://doi.org/10.1016/S0079-6603(00)63004-8 [4] **Penning, T. M.** (2010). New frontiers in androgen biosynthesis and metabolism. *Current Opinion in Endocrinology, Diabetes and Obesity*, 17(3), 233–239. https://doi.org/10.1097/MED.0b013e3283386a31 [5] **Mostaghel, E. A., & Nelson, P. S.** (2008). Intracrine androgen metabolism in prostate cancer progression: Mechanisms and clinical implications. *Journal of Steroid Biochemistry and Molecular Biology*, 108(3-5), 237–243. https://doi.org/10.1016/j.jsbmb.2007.09.010 [6] **Kedishvili, N. Y.** (2016). Retinoic acid synthesis and degradation. *Subcellular Biochemistry*, 81, 127–161. https://doi.org/10.1007/978-94-024-0945-1_5 [7] **Chang, K. H., Li, R., Papari-Zareei, M., et al.** (2011). Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. *Proceedings of the National Academy of Sciences*, 108(33), 13728–13733. https://doi.org/10.1073/pnas.1107898108 [8] **Belyaeva, O. V., & Kedishvili, N. Y.** (2002). Comparative genomic analysis of the short-chain dehydrogenase/reductase (SDR) family in the human genome. *Genomics*, 80(5), 522–530. https://doi.org/10.1006/geno.2002.6855 [9] **Jansson, A. K., Gunnarsson, C., Cohen, M., et al.** (2006). 17β-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. *Cancer Research*, 66(23), 11471–11477. https://doi.org/10.1158/0008-5472.CAN-06-1448 [10] **Kallberg, Y., Oppermann, U., Jörnvall, H., & Persson, B.** (2002). Short-chain dehydrogenase/reductase (SDR) relationships: A large family with eight clusters common to human, animal, and plant genomes. *Protein Science*, 11(3), 636–648. https://doi.org/10.1110/ps.26902 [11] **Luu-The, V.** (2013). Assessment of steroidogenesis and steroidogenic enzyme functions. *Journal of Steroid Biochemistry and Molecular Biology*, 137, 176–182. https://doi.org/10.1016/j.jsbmb.2013.05.017 [12] **Prakash, C., & Zuniga, A.** (2016). Retinoic acid in the developing brain: A key player in neurogenesis and synaptic plasticity. *Neural Regeneration Research*, 11(9), 1412–1413. https://doi.org/10.4103/1673-5374.191213 [13] **Sharifi, N.** (2013). Mechanisms of androgen receptor activation in castration-resistant prostate cancer. *Endocrinology*, 154(11), 4010–4017. https://doi.org/10.1210/en.2013-1466 [14] **Vihko, P., Härkönen, P., Soronen, P., et al.** (2004). 17β-hydroxysteroid dehydrogenases and cancers. *Journal of Steroid Biochemistry and Molecular Biology*, 92(4), 281–290. https://doi.org/10.1016/j.jsbmb.2004.10.004 [15] **Zhang, Y., & Dufort, I.** (2014). The role of 17β-hydroxysteroid dehydrogenases in the regulation of steroid hormone action. *Molecular and Cellular Endocrinology*, 382(1), 587–597. https://doi.org/10.1016/j.mce.2013.08.006 --- ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)